Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Purification and characterization of mutant miniPlasmin for thrombolytic therapy.

Lin X, Wang Y, Zhang Y, Huang B, Lin JJ, Hallock SJ, Yu H, Shao H, Yan J, Huang B, Zhang XC, Cao W, Xu X, Lin X.

Thromb J. 2013 Jan 30;11(1):2. doi: 10.1186/1477-9560-11-2.

2.

Refolding, purification, and activation of miniplasminogen and microplasminogen isolated from E. coli inclusion bodies.

Medynski D, Tuan M, Liu W, Wu S, Lin X.

Protein Expr Purif. 2007 Apr;52(2):395-402.

PMID:
17126563
3.

Thrombolytic agents in development.

Verstraete M, Lijnen HR, Collen D.

Drugs. 1995 Jul;50(1):29-42. Review.

PMID:
7588087
4.

Newer thrombolytic agents.

Verstraete M.

Ann Acad Med Singapore. 1999 May;28(3):424-33. Review.

PMID:
10575530
5.

[Development of new thrombolytic substances].

Zeymer U, Neuhaus KL.

Herz. 1994 Dec;19(6):314-25. Review. German.

PMID:
7843688
6.

Remaining perspectives of mutant and chimeric plasminogen activators.

Lijnen HR, Collen D.

Ann N Y Acad Sci. 1992 Dec 4;667:357-64. Review.

PMID:
1309056
7.

Simplified recombinant plasmin: production and functional comparison of a novel thrombolytic molecule with plasma-derived plasmin.

Hunt JA, Petteway SR Jr, Scuderi P, Novokhatny V.

Thromb Haemost. 2008 Sep;100(3):413-9.

PMID:
18766256
8.

Alfimeprase.

[No authors listed]

Drugs R D. 2008;9(3):185-90.

PMID:
18457471
10.

Function of the central domain of streptokinase in substrate plasminogen docking and processing revealed by site-directed mutagenesis.

Chaudhary A, Vasudha S, Rajagopal K, Komath SS, Garg N, Yadav M, Mande SC, Sahni G.

Protein Sci. 1999 Dec;8(12):2791-805.

11.

Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.

Collen D, Lu HR, Lijnen HR, Nelles L, Stassen JM.

Circulation. 1991 Sep;84(3):1216-34.

PMID:
1909220
12.

Plasminogen mutants activated by thrombin. Potential thrombus-selective thrombolytic agents.

Dawson KM, Cook A, Devine JM, Edwards RM, Hunter MG, Raper RH, Roberts G.

J Biol Chem. 1994 Jun 10;269(23):15989-92.

13.

[The fibrinolytic system and its activators].

Seifried E.

Z Gesamte Inn Med. 1993 Jun-Jul;48(6-7):272-82. Review. German.

PMID:
8333223
14.

The thrombolytic effect of miniplasmin in a canine model of femoral artery thrombosis.

Fu J, Ren J, Zou L, Bian G, Li R, Lu Q.

Thromb Res. 2008;122(5):683-90. doi: 10.1016/j.thromres.2008.01.007.

PMID:
18328540
15.

Initial characterization of autoprocessing and active-center mutants of CMV proteinase.

Snyder SW, Edalji RP, Lindh FG, Walter KA, Solomon L, Pratt S, Steffy K, Holzman TF.

J Protein Chem. 1996 Nov;15(8):763-74.

PMID:
9008301
16.

Thrombolysis for acute ischaemic stroke.

Wardlaw JM, Zoppo G, Yamaguchi T, Berge E.

Cochrane Database Syst Rev. 2003;(3):CD000213. Review. Update in: Cochrane Database Syst Rev. 2009;(4):CD000213.

PMID:
12917889
17.

Development of thrombolytic therapy for stroke: a perspective.

Lapchak PA.

Expert Opin Investig Drugs. 2002 Nov;11(11):1623-32. Review.

PMID:
12437508
18.

Considerations affecting selection of thrombolytic agents.

Smitherman TC.

Mol Biol Med. 1991 Apr;8(2):207-18. Review.

PMID:
1806763
20.

The effect of the one-chain to two-chain conversion in tissue plasminogen activator: characterization of mutations at position 275.

Higgins DL, Lamb MC, Young SL, Powers DB, Anderson S.

Thromb Res. 1990 Feb 15;57(4):527-39.

PMID:
2139248
Items per page

Supplemental Content

Support Center